Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of DW5221 (megestrol acetate) in healthy male volunteers
NCT06147908Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of megestrol in anorexia nervosa (AN) and cachexia (2 arms), sponsored by Daewon Pharm. Primary endpoints: Peak Plasma Concentration up to 120 hours and Area under the plasma concentration versus time curve up to 120 hours. Started Jul 2022; status: completed.
02
Drugs
megestrol
03
Conditions
anorexia nervosa (AN)cachexia
Beyond the preview
Go deeper on NCT06147908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147908.